 | • レポートコード：B-MOR-08375 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、マイコプラズマ検査の世界市場について調べ、マイコプラズマ検査の世界規模、市場動向、市場環境、製品別（検査装置、キット・試薬）分析、技術別（PCR、ELISA、直接アッセイ、間接アッセイ、微生物培養技術、その他）分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・マイコプラズマ検査の世界市場インサイト ・マイコプラズマ検査の世界市場環境 ・マイコプラズマ検査の世界市場動向 ・マイコプラズマ検査の世界市場規模 ・マイコプラズマ検査の世界市場規模：製品別（検査装置、キット・試薬） ・マイコプラズマ検査の世界市場規模：技術別（PCR、ELISA、直接アッセイ、間接アッセイ、微生物培養技術、その他） ・マイコプラズマ検査の世界市場規模：用途別 ・マイコプラズマ検査の世界市場：地域別市場規模・分析 ・マイコプラズマ検査の北米市場規模・予測 ・マイコプラズマ検査のアメリカ市場規模・予測 ・マイコプラズマ検査のヨーロッパ市場規模・予測 ・マイコプラズマ検査のアジア市場規模・予測 ・マイコプラズマ検査の日本市場規模・予測 ・マイコプラズマ検査の中国市場規模・予測 ・マイコプラズマ検査のインド市場規模・予測 ・マイコプラズマ検査の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global mycoplasma testing market is expected to register a CAGR of 10.4% during the forecast period of 2018–2023. North America is anticipated to dominate the market during the forecast period owing to the large number of life science research activities conducted in this region.
High Spending into R&D Activities by Bio-pharmaceutical Companies
The R&D spending by pharmaceutical companies has been steadily increasing over the past few years, both in the developed and the emerging countries. This was mainly attributed to the increased number of patent expirations, which resulted in a patent cliff in 2012 and is expected to continue for another decade. As a result of the patent expiration, most blockbuster molecules will no longer be able to generate revenue and pharmaceutical companies have no other option but to develop new revolutionary molecules for survival. Therefore, the companies are increasing their spending on R&D to accelerate the process of drug discovery and development. Mycoplasma detection and removal is critical for biologics produced for clinical studies and licensed products for human use. Thus, increase in drug discovery and development process from pharmaceutical companies is likely to augment the demand for mycoplasma testing, which will drive the global mycoplasma testing market. Additionally, increased governmental initiatives and funding in research activities, increasing demand for fast, accurate and affordable testing, and increasing cell culture contamination are further driving the market for mycoplasma testing.
Stringent Government Regulations
Stringent government regulations are likely to hinder the mycoplasma testing market growth. The regulations implemented include the assessment of nutritive properties of the solid growth media (agar) used, the assessment of inhibitory substances in the test material, the incubation temperature ranges to be used, and the number and types of positive controls to be used. These stringent government regulations act as the major restraining factors for the market. Additionally, a high degree of consolidation for new entrants may impede the market.
North America to Dominate the Market
North America dominates the mycoplasma testing market. The factors attributing to the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment into R&D activities in the region. Asia-Pacific is anticipated to grow tremendously during the forecast period owing to factors, such as rapid research activities conducted by the pharmaceutical and biotechnology industries and the huge amount of spending in R&D activities, thereby boosting the demand for mycoplasma testingproducts.
Key Developments in the Market
• April 2017: Thermo Fisher Scientific entered into a partnership with Australian diagnostics firm SpeeDx to obtain US Food and Drug Administration approval for its Resistance Plus MG assay for antibiotic-resistant Mycoplasma genitalium.
Major players- ABBOTT, AGILENT TECHNOLOGIES, CHARLES RIVER LABORATORIES INTERNATIONAL, INC., EUROFINS SCIENTIFIC, F. HOFFMANN-LA ROCHE LTD, LONZA GROUP, MERCK KGAA, PROMOCELL GMBH, SARTORIUS AG, AND THERMO FISHER SCIENTIFIC, INC., amongst others.
Reasons to Purchase the Report
• Follow the current and future global mycoplasma testing market in the developed and emerging markets.
• Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Increased Governmental Initiatives and Funding in Research Activities
6.1.2 Higher Investment into R&D Activities
6.1.3 Increasing Demand for Fast, Accurate, and Affordable Testing
6.1.4 Increasing Cell Culture Contamination
6.2 Restraints
6.2.1 Stringent Government Regulations
6.2.2 High Degree of Consolidation for New Entrants
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Product
7.1.1 Instruments
7.1.2 Kits and Reagents
7.2 By Technology
7.2.1 PCR
7.2.2 ELISA
7.2.3 Direct Assay
7.2.4 Indirect Assay
7.2.5 Microbial Culture Techniques
7.2.6 Others
7.3 By Application
7.3.1 Cell Line Testing
7.3.2 Virus Testing
7.3.3 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.1.4 Rest of North America
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC Countries
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott
9.2 Agilent Technologies
9.3 Charles River Laboratories International, Inc.
9.4 Eurofins Scientific
9.5 F. Hoffmann-La Roche Ltd
9.6 Lonza Group
9.7 Merck KGaA
9.8 PromoCell GmbH
9.9 Sartorius AG
9.10 Thermo Fisher Scientific, Inc.
9.11 List not Exhaustive
10. Future of the Market